Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Part of paid clinical trials in Newark, New Jersey.
- Sponsor
- Bhagat, Neelakshi, M.D., M.P.H.
- Study ID
- NCT01069341
- Phase
- PHASE1
- Status
- Completed
Conditions
- Proliferative Diabetic Retinopathy
- Rubeosis Iridis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — DRUGIntravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
Study Details
The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of proliferative diabetic retinopathy (PDR).
Key Dates
- First listed
- Feb 17, 2010
- Start date
- Jul 31, 2007
- Status verified
- Sep 2012
- Primary completion
- Dec 31, 2011
- Completion
- Jan 31, 2012
Study Design
- Enrollment
- 4 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: TreatmentAll subjects enrolled received treatment with identical dosage of Ranibizumab
Primary Outcome Measure
Adverse Event (AE) [ Time Frame: first 12 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Njms / Umdnj | Newark | New Jersey | 07103 | - |
Find similar trials in Newark, NJ
By condition
By specialty
By research site